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 “If food gets stuck in your throat you have to go                                      
to the doctor and be vaccinated, or poke it away with a                                
small forceps, otherwise you will be small...                                                   
The body NEEDS food " 
Rebecka, 4 years old. 
   “Om det är stopp i matstrupen måste man åka till doktorn och bli                             
 vaccinerad, eller pilla bort det med en liten tång, annars blir man liten… 
För kroppen MÅSTE ha mat” 
Rebecka, 4 år. 
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ABSTRACT 
Eosinophilic esophagitis (EoE) is an inflammatory disorder of the esophagus 
characterized by symptoms of esophageal dysfunction and eosinophilia in the 
esophageal mucosa. This condition may affect approximately 1% of the 
general population and is strongly associated with allergy/atopic diatheses. 
Aims: The overall aim of this thesis was to examine the clinical aspects on 
the management of patients with EoE. The possibility of a seasonal variation 
of food bolus impaction in the esophagus, a common complication of EoE 
patients, was explored. The burden of symptoms and health-related quality of 
life (HRQL) of patients with EoE at diagnosis, after two months of treatment 
and at a long-term follow-up point were investigated. The association 
between the grade of mucosal eosinophilia and the symptoms was studied. 
Methods & Results: Subjects with bolus impaction (n=314) were included 
in a retrospective study. A significantly higher incidence of bolus impaction 
was found in subjects with atopic disorders during the fall (n=90) than during 
any of the other three seasons (p=0.015). Untreated EoE patients were 
included in two prospective studies (n=31 and n=47, respectively). 
Symptoms and HRQL (Watson Dysphagia Scale, EORTC QLQ-OES18, SF-
36) were evaluated at diagnosis, after two months of treatment with topical 
corticosteroids and at least one year after inclusion (median: 23 months after 
inclusion). The dysphagia-related scores improved after treatment and a 
partial remission was noted at the long-term follow-up point. The grade of 
mucosal eosinophilia in untreated patients with dysphagia and esophageal 
eosinophilia  (n=65) was assessed using both hematoxylin-eosin staining and 
immunohistochemical technique. No correlation was found between the 
grade of eosinophilia and the symptoms/HRQL using the aforementioned 
questionnaires, however, a higher grade of eosinophilia was found among 
patients with concomitant bolus impaction as compared to those without.  
 Conclusions: A seasonal variation was found in the incidence of acute 
esophageal bolus impaction in patients with atopic disorders. EoE patients 
had a substantial burden of symptoms, which improved after treatment, and a 
partial remission was noted more than one year after diagnosis. A high grade 
of eosinophilia in the proximal part of the esophagus might serve as a marker 
for an increased risk of bolus impaction. 
Keywords: eosinophilia, esophagitis, dysphagia, quality of life, bolus 
impaction. 
ISBN: 978-91-628-9360-6, http://hdl.handle.net/2077/38467  
SAMMANFATTNING PÅ SVENSKA 
Eosinofil esofagit (EoE), eller ”allergisk matstrupe” som det kallas i folkmun, 
är ett inflammatoriskt tillstånd i matstrupen som orsakar sväljningsbesvär och 
i många fall även totalstopp pga. att föda fastnar. För att ställa diagnosen 
krävs att patienten har associerade besvär och att man ser en ansamling av 
eosinofila celler i biopsier från matstrupsslemhinnan. Sjukdomen är starkt 
kopplad till andra allergiska sjukdomar såsom luftvägs- och 
födoämnesallergier samt astma. Prevalensen i den svenska 
normalbefolkningen är sannolikt ca 1% och såväl barn som vuxna kan 
drabbas. Flera olika behandlingsalternativ har prövats och idag 
rekommenderas i första hand lokal kortisonbehandling alternativt modifierad 
kost.  
Syftet med denna avhandling och dess ingående studier är att belysa olika 
aspekter som berör det kliniska handläggandet av patienter med EoE. Vi ville 
undersöka en eventuell förekomst av säsongsvariation av patienter som sökt 
sjukvård pga. totalstopp i esofagus, en vanlig komplikation till EoE. Vidare 
önskade vi utvärdera symptom och hälsorelaterad livskvalitet hos patienter 
med EoE vid diagnos, efter två månaders lokal kortisonbehandling samt vid 
uppföljning minst ett år senare. Slutligen ville vi utvärdera eventuella 
samband mellan symptom och grad av eosinofili i matstrupsslemhinnan.    
I en retrospektiv studie inkluderades under en 6-årsperiod, patienter (n=314) 
som sökt pga. totalstopp i matstrupen. Patienter med samtidig atopisk 
sjukdom (n=90) hade en större incidens under hösten jämfört med de övriga 
årstiderna. I två prospektiva studier (n=31 resp. n=47) inkluderades 
obehandlade EoE patienter. Symtom och livskvalitet mättes med hjälp av 
frågeformulär vid diagnos, efter två månaders lokalbehandling med kortison 
och vid en långtidsuppföljning minst ett år senare. De sväljningsrelaterade 
symtomen minskade efter behandlingen och vid uppföljning minst ett år 
senare (medeltid två år) kvarstod en lägre grad av symtombelastning jämfört 
med före behandling. I den sista studien fann vi att graden av eosinofili i 
matstrupsslemhinnan hos patienter med samtidiga sväljningssvårigheter 
(n=65) inte korrelerar med symtomgrad eller livskvalitet mätt med 
frågeformulär. Däremot fann vi en ökad grad av eosinofili i övre delen av 
matstrupsslemhinnan hos patienter med samtidig förekomst av totalstopp i 
matstrupen jämfört med de som inte hade detta.  
Sammanfattningsvis var den observerade säsongsvariationen i incidens av 
främmande kropp i matstrupen accentuerad vid samtidig förekomst av 
atopisk sjukdom. Obehandlade patienter med EoE hade en hög symtombörda 
 vilken minskade efter en 2-månaders kur med lokal kortisonbehandling och 
en viss kvarstående effekt av behandlingen sågs mer än ett år senare. 
Slutligen skulle en ökad förekomst av eosinofiler i slemhinnan i den övre 
delen av matstrupen kunna ha ett samband med en ökad risk för att drabbas 
av främmande kropp i matstrupen. 
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ABBREVIATIONS 
EMBP Eosinophil Major Basic Protein 
ENT Ear, Nose and Throat 
EoE Eosinophilic esophagitis 
EORTC European Organization for Research and Treatment of 
Cancer 
GERD Gastro-Esophageal Reflux Disease 
HE Hematoxylin and Eosin 
HPF              High-Power Field 
HRQL Health-Related Quality of Life 
IHC Immunohistochemical 
IL Interleukin 
LES Lower Esophageal Sphincter 
NÄL 
PPI 
Norra Älvsborgs Länssjukhus 
Proton-Pump Inhibitor 
PPI-REE Proton-Pump Inhibitor-Responsive Esophageal 
Eosinophilia 
PRO Patient-Reported Outcomes 
QLQ-C30 Quality of Life Questionnaire Core 30 
QLQ-OES18 Quality of Life Questionnaire Oesophageal Module 18 
QoL Quality of Life 
SF-36 Short Form-36 
Th2 T helper-2 cell 
UES Upper Esophageal Sphincter 
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1 INTRODUCTION 
This thesis concerns the management of adult patients with eosinophilic 
esophagitis (EoE), an allergic, inflammatory disease affecting the esophagus 
and one of the leading causes of esophageal dysphagia.1  
 
1.1 The Esophagus 
The esophagus develops from the foregut at the fifth gestational week when 
the early foregut differentiates into the respiratory tract and the intestinal 
tract. The two organ systems share their early developmental background, 
although some details regarding the development are controversial.2 The 
esophagus represents the first part of the alimentary tract linking the pharynx 
to the stomach. It passes through the thorax, behind the heart and trachea and 
between the lungs (Figure 1). It is a muscular tube of 20-22 cm, the wall is 
composed of four layers; the mucosa, the submucosa, the muscularis propria 
and the adventitia.3 The mucosa consists of a nonkeratinized squamous 
epithelium with a thin layer of connective tissue, glands and lymphatic 
vessels (the lamina propria). Between the mucosa and the submucosa, there is 
a thin layer of smooth muscle fibers (the muscularis mucosa). The submucosa 
consists mainly of connective tissue and includes blood vessels and mucosal 
glands. The muscularis propria has a circular inner and an outer, longitudinal 
muscular layer. The adventitia is the external fibrous layer, which connects 
the esophagus to the surrounding structures. It is composed of loose 
connective tissue containing small blood vessels, lymphatic vessels and nerve 
fibers (Figure 2).3, 4 
The most proximal border of the esophagus is the upper esophageal sphincter 
(UES), also called the cricopharyngeal sphincter. The UES as well as the 
proximal part of the esophagus contains striated muscle fibers. The transition 
to smooth muscle fibers occurs in the mid-portion of the esophagus, and the 
distal part contains only smooth muscle. The innervation changes from 
central innervation in the proximal part to mainly autonomic innervation in 
the distal part, including in the lower esophageal sphincter (LES). The LES is 
the gastro-esophageal junction and is a closed 3-4 cm high-pressure zone that 
protects the acid-sensitive mucosa of the esophagus from reflux of the 
stomach contents.3 
Helen Larsson 
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Figure 1. The position and relationships of the esophagus in the cervical region and 
posterior mediastinum. Seen from behind. (Source: Henry Gray, Anatomy of the 
human body, Plate 1032) 
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Figure 2. Cross-section of the esophagus. Printed with 
permission from Primal Pictures.  
 
The swallowing act is a complex process comprising three different phases, 
the oral, pharyngeal and esophageal phases. The oral phase is voluntary and 
includes masticating and moistening the food and transforming it into a bolus 
using the teeth, tongue and salivary glands. The bolus is pushed backward 
toward the pharynx using the lingual muscles and the tongue. The pharyngeal 
phase is involuntary and is the most critical phase of swallowing because the 
food and airway cross in the pharynx, demanding smooth neuromuscular 
cooperation involving the 5th, 7th, 9th, 10th and 12th cranial nerves. In less than 
two seconds, as the bolus is pushed into the pharynx, the soft palate is 
elevated, blocking the passage upward to the nasopharynx, the larynx and the 
hyoid bone are elevated, causing a passive tilt of the epiglottis to cover the 
glottis, the vocal cords are strongly approximated to protect the trachea, and 
the UES relaxes, allowing the bolus to pass into the esophagus. 
The esophageal passage of the bolus is involuntary, and under optimal 
conditions, when a person is in the upright position, gravity in combination 
with the movement of the bolus from the pharyngeal phase is generally 
sufficient. Even so, to facilitate this passage and to clear the esophagus of the 
bolus, contractions of the circular muscle layer narrows the lumen and 
contractions of the longitudinal muscle layer shortens the esophageal tube, 
creating a peristaltic movement. Activation of the contractions is both a 
continuation of the peristaltic wave that begins during the pharyngeal 
swallowing phase and a neurological response to the distension of the 
esophagus by the passing bolus. The peristaltic waves continue until the 
bolus has passed the esophagus and moved into the stomach.3-5  
Helen Larsson 
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1.2 Dysphagia 
Difficulty in performing the swallowing act is called dysphagia. The 
prevalence of this symptom in the general population ranges from 1.7% to 
11.3%.6, 7 Several underlying diseases that cause dysphagia occur at various 
ages. In the elderly population, neurological diseases are the main causes, 
e.g., dementia and Parkinson’s disease. In the middle-aged population, other 
neurological diseases, immunological disorders and diseases associated with 
the local dysfunction of the esophagus, including achalasia, nut-cracker 
esophagus and EoE are common causes of dysphagia. In children, infections, 
EoE, prematurity or cerebral palsy may be responsible for this dysfunction.7 
Dysphagia can be divided into two categories depending on anatomic 
location: oropharyngeal and esophageal. 
Oropharyngeal dysphagia is generally characterized by coughing and 
drooling during the early onset of eating. It is a common symptom of 
neuromuscular diseases, including stroke, amyotrophic lateral sclerosis, 
Parkinson’s diseases and multiple sclerosis, and of diseases that affect the 
function of the salivary glands and thereby reduce the moisturizing of the 
bolus, e.g., Sjögren’s syndrome.3   
Patients with esophageal dysphagia often complain about the feeling that 
food becomes stuck or only slowly slips down to the stomach or that they 
need to vomit. It can be caused by a mechanical obstruction or by a 
neuromuscular disorder affecting the esophageal motility. Diseases causing 
motility disorders are generally associated with dysphagia for both liquids 
and solid food, whereas obstructive disorders generally present with 
dysphagia for solids. Obstruction may be caused by strictures (e.g., those due 
to peptic reflux, caustic damage or radiation), rings or webs, benign or 
malignant tumors, congenital anomalies or EoE. Patients with peptic 
strictures frequently have a long history of heartburn and other symptoms 
related to gastro-esophageal reflux disease (GERD). A rapidly progressing 
dysphagia in combination with weight loss and a poor general condition 
should raise a strong suspicion of malignant tumor as the underlying cause, 
and prompt urgent investigation.3, 4  
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1.3 Esophageal Bolus Impaction 
Esophageal bolus impaction occurs in both children and adults and has a 
multifaceted etiology. Children may accidentally swallow toys, coins, and 
other sharp or hard items while playing, whereas adolescents and adults with 
a psychiatric background may intentionally swallow sharp items. In geriatric 
patients, esophageal dysphagia due to neuromotor disturbances or bad 
dentures may be the cause of esophageal obstruction. In addition to prior 
surgery to treat esophageal atresia or fundoplication, EoE is the most 
common underlying condition of esophageal bolus obstruction, particularly 
among young and middle-aged patients.8 Studies have shown that as many as 
30-50% of patients with esophageal bolus impaction have concomitant EoE.9-
11 The estimated annual incidence of bolus impaction is 11-19 episodes per 
100.000 inhabitants, with a male preponderance (1.4-2.3:1). Most patients 
(86-99%) admitted to hospital due to esophageal bolus impaction require 
bolus retrieval, a procedure generally performed using flexible endoscopy.9, 
12-14 In Sweden, the ENT-surgeon is generally consulted and often performs 
rigid and flexible techniques under general anesthesia. In the majority of 
other countries, however, gastroenterologists and/or gastrointestinal surgeons 
more commonly treat these patients.  
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1.4 The Eosinophil 
The eosinophil granulocyte is a fascinating cell that was first described in the 
mid-1800s (Figure 3). It was named in 1879 based on its strong avidity to the 
acidic dye, eosin, by the German physician Paul Ehrlich, who won the Nobel 
Prize in 1908 for his contributions to the field of immunology. Eosinophil 
granulocytes comprise 1–4% of the leukocytes in the bloodstream and are 
associated with T helper-2 (Th2) cells in allergic and anti-parasitic host 
immune responses.1, 15  
 
Figure 3. The Eosinophil (Source: Blausen gallery 2014. Wikiversity Journal of 
Medicine. DOI:10.15347/wjm/2014.010. ISSN: 20018762.) 
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Eosinophils develop from myeloid precursor cells within the bone marrow, 
where they mature for 2–6 days before migrating into the bloodstream. They 
remain in the bloodstream for hours before migrating, which in healthy 
individuals is primarily to tissues and organs exposed to the external 
environment, such as the submucosa and loose connective tissue of the skin, 
the gastrointestinal tract (except for the healthy esophagus), the genital tract 
and the lungs.1, 15, 16 The development, maturation and migration of 
eosinophils is governed by cytokines, particularly interleukin-5 (IL-5), that 
are produced mainly by the Th2 cells. The release of cytokines is part of the 
immunological process and is a response to an infectious agent, e.g., a 
parasite, or an allergic response to an antigen. An antigen-presenting cell 
(e.g., dendritic cells, macrophages or B-cells) activates a Th2 cell to produce 
and release the eosinophil-activating cytokines.1 An eosinophil itself may act 
as an antigen-presenting cell, and it has been shown that circulating 
eosinophils display a distinctive disease-specific cytokine pattern.17, 18  
Vesicles in the cytoplasm of eosinophils contain pro-inflammatory granules 
including basic proteins; interleukins, lipid mediators, cytokines, 
chemokines, growth factors and autocrine survival factors. When eosinophils 
are activated, the eosinophilic granules are released into the target tissue, 
causing local inflammation. The released granulae are cytotoxic, neurotoxic 
and tissue damaging. The airway and lung tissues of patients with 
eosinophilic asthma display epithelial cell damage, fibrosis and 
angiogenesis.1, 19 
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1.5 Eosinophilic Esophagitis 
EoE is an allergic, inflammatory disorder of the esophagus that causes 
swallowing difficulties and the potentiality for severe complications.1  
 
1.5.1 History 
EoE has a fairly short history as a clinical entity. The knowledge of and 
interest in this disease has increased greatly over the last two decades. The 
first publication concerning EoE, in the late 1970s, was a case-report of a 
patient with eosinophilic esophagitis in combination with severe achalasia.20 
In the 1980s, an eosinophilic inflammation of the esophageal mucosa was 
associated with GERD, and it was not until 1993 that the British Professor of 
Surgery Stephen Attwood described the combination of dysphagia and 
eosinophilia and recognized EoE as a separate disease entity.21, 22 In 2007, a 
systematic review of the literature was conducted by an international group of 
experts, followed by the publication of consensus recommendations 
regarding the diagnosis and treatment of EoE..23 Updated recommendations 
were published in 2011 and 2013, and the first textbook concerning EoE was 
printed in 2012.1, 24, 25 
 
1.5.2 Prevalence, Etiology and Pathogenesis 
EoE is a chronic immune/antigen-mediated disease of the esophagus 
affecting people of all ages, with a male to female ratio of approximately 
3:1.1, 25 The reported prevalence varies considerably, with fewer registered 
cases in medical care units than in samples from the general population.26-28 
A Swedish population study (n=1000) reported a 0.7% prevalence of 
probable EoE, but the prevalence figures range from 10-59/100 000 in 
different studies.26, 29-31 Similar to other allergic ailment, both the prevalence 
and incidence of EoE appear to be increasing. 27, 28  
The true etiology of EoE is not yet known. However, studies in both children 
and adults have verified that EoE is an antigen-driven allergic condition.1, 24 
There is marked over-representation (approximately 70%) of a personal 
history of allergy, atopic conditions and/or asthma among patients with EoE, 
and it has been shown that eliminating food allergen in pediatric patients has 
both histological and clinical beneficial effects; recently, similar results have 
been observed also in adults.24, 32-35  
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The role of eosinophils in the pathogenesis of EoE is also not yet entirely 
understood. These cells are thought to contribute to angiogenesis, which 
increases the supply of inflammatory blood cells, adding more eosinophils to 
the target tissue. Furthermore, eosinophils induce the proliferation of the 
esophageal epithelial cells, causing basal-zone hyperplasia and esophageal 
thickening. Myofibroblasts are also activated by eosinophils, proliferating 
and eventually causing subepithelial fibrosis, which contributes to the 
luminal narrowing and stricture formation observed in these patients.36, 37 A 
delayed diagnosis, and thereby a prolonged eosinophilic inflammation, has 
been shown to increase the risk of esophageal stricture formation.38 Other 
features contributing to the rigidity of the esophageal wall are the 
proliferation and hyperplasia of the smooth muscle cells. Altogether, these 
processes are believed to cause the symptoms, morphological changes and 
complications observed in patients with EoE.1, 36  
 
1.5.3 Symptoms and Diagnosis  
The typical adult EoE-patient is a middle-aged atopic man with a long history 
of solid-food dysphagia who commonly presents with a history of total 
esophageal obstruction by food that must be retrieved. Heartburn or upper 
abdominal pain are less commonly reported but may occur.1 In small 
children, symptoms related to EoE are failure to thrive, feeding difficulties, 
vomiting and pain.25 The average duration of symptoms before diagnosis may 
be as long as 4-5 years.1 
EoE is a clinicopathological disease, the diagnosis of which should be 
established according to current guidelines. These criteria include; i. at least 
one biopsy from the esophageal mucosa showing eosinophilic inflammation 
with >15 eosinophils/high-power field (HPF) (peak value), ii. symptoms 
related to esophageal dysfunction and iii. exclusion of other causes of 
esophageal eosinophilia, such as proton-pump inhibitor-responsive 
esophageal eosinophilia (PPI-REE).24, 25 Endoscopy should be performed and 
2–4 biopsy samples from the distal and proximal esophagus should be 
collected. The eosinophilic infiltration of the esophageal mucosa is known to 
be patchy, and two and three biopsies have been shown to have a diagnostic 
sensitivity of 84% and 97.24 Complementary biopsies from the ventricle and 
duodenum should always be obtained from children and adults if other 
diseases that might be associated with esophageal eosinophilia are suspected. 
The latter diseases include GERD, celiac or Crohn’s disease, parasitic 
infections, vasculitis or drug hypersensitivity.24, 25  
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The association between GERD and EoE has not yet been fully explored. The 
two diseases overlap both histologically and symptomatically, although 
dysphagia is not as commonly observed in GERD patients as in EoE patients. 
While the number of eosinophils is often higher in EoE patients, histological 
signs of their effects, such as eosinophilic microabscesses, basal cell 
hyperplasia and dilated intercellular spaces are more commonly observed in 
EoE patients than in GERD-patients.39  
 
Endoscopic findings  
The typical endoscopic findings in EoE patients are esophageal rings 
(trachealization), strictures and a narrow-caliber esophagus (prevalence: 44%, 
21% and 9%, respectively). Findings more prevalent in children are linear 
furrows, white plaques, and decreased vascularization (prevalence: 48%, 27% 
and 41%, respectively) (Figure 4).40 None of these endoscopic features are, 
however, pathognomonic for EoE because they may occur in those with other 
esophageal disorders.25 Furthermore, endoscopic examination have been 
reported to be normal in approximately 17% of EoE patients. 40  
 
Figure 4. Endoscopic findings of EoE, including trachealization, linear furrows and 
white plaques. Photo: Dr. Mogens Bove.  
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Histological findings  
Over the years, the peak number of eosinophils/HPF necessary to fulfill the 
diagnostic criteria of EoE has varied. However the consensus 
recommendation of 2007 of >15 eosinophils/HPF has become the established 
cut-off value.23 A HPF is the area visible in a microscope under the maximum 
magnification, generally x400. Unfortunately, the area of a HPF has not been 
stringently defined and it might differ according to the objective lens used. In 
a review article published in 2007, the area of a HPF was found to range from 
0,12 to 0,44 mm2 in the few publications in which it was specified. 
Consequently, the possibility of specifying the area of a HPF in mm2 is being 
discussed.41  
In addition to the elevated number of eosinophils per HPF, several other 
characteristic histological signs are commonly found in biopsies of the 
esophageal mucosa of EoE patients. These findings include clusters of four or 
more eosinophils (eosinophilic microabscesses), eosinophilic degranulation, 
superficial layering, dilated intercellular spaces, basal cell hyperplasia and 
fibrosis of the lamina propria (Figures 5 and 6). Although the latter 
histological signs strongly indicate EoE, none of them are pathognomonic.39  
 
 
 
Figure 5. Histological image of a biopsy obtained from the esophageal mucosa of an 
EoE patient. Signs of inflammation with pronounced prolongation of the papillae 
nearly reaching the epithelial surface. 
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Figure 6. Histological images of biopsies obtained from the esophageal mucosa of 
an EoE patient. At the top: eosinophilic microabscesses In the middle: eosinophilic 
degranulation. At the bottom: dilated intercellular spaces. 
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1.5.4 Treatment  
Several treatment strategies for EoE have been implemented including anti-
allergic medication; allergen elimination diet, esophageal dilatation and 
proton-pump inhibitors (PPI) (Table 1).23-25 The current first-choice therapy 
for adults are topical corticosteroids which, administered as an aerosol or 
viscous suspension, have beneficial effects both histologically, with a 
reduced eosinophilic load observed, and in terms of clinical improvement.24, 
25, 42 The length of the treatment described in different studies has ranged 
from two weeks to two months, and the corticosteroids most commonly used 
are fluticasone and budesonide.42-44 Side-effects appear to be mild and are 
reasonably rare and include oral mucositis. According to current 
recommendations, topical corticosteroid therapy for EoE patients should be 
individually selected, and therefore the type of steroid and duration of 
treatment have not been specified.24 A few longitudinal studies have been 
conducted, but the potential need for long-term treatment with steroids has 
not yet been fully evaluated.24, 25 EoE patients who achieved histological 
remission and relief of symptoms after a high-dose short-term (15 days) 
course of budesonide treatment have been found to maintain long-term 
remission by continuing with a lower dose.45 In a three-year follow-up study, 
repetitive treatment was required to suppress recurrent symptoms after an 
initial 6-week course of high-dose fluticasone treatment.46 Moreover, in a 
five-year follow-up study, treatment with oral topical corticosteroids reduced 
the risk of esophageal food impaction and the requirement for endoscopic 
food retrieval.47  
Because food allergies have been estimated to affect approximately 6% of the 
European population and EoE is known to be an immune-mediated disorder 
that can be triggered by food antigens, dietary allergen elimination would, at 
least theoretically, be expected to have a high impact on the disease.1, 48 
Allergen-elimination diets have been successfully used in children and 
recently, studies have reported beneficial effects in adults.34, 35, 49 The most 
frequent EoE triggers in both adults and children appear to be cow’s milk, 
soy, wheat, seafood and peanuts. After reintroducing each food, an evaluation 
of the clinical effect as well as endoscopic and histological evaluations may 
be warranted to identify specific food triggers.34, 35 However, a dietary 
elimination treatment requires a major effort from the patient and is not 
always feasible. 
According to some studies, approximately one-fifth of adult EoE patients 
develop esophageal strictures.40 Esophageal dilatation may offer symptom 
relief but it does not affect the underlying inflammatory process. This 
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procedure is associated with rare but severe side effects, including esophageal 
perforation and bleeding, which occurs in less than 1% of the cases. 
Therefore, the procedure should be performed with caution and in well-
selected patients.50-52  
Because EoE is known to be an allergen-driven Th2-type inflammatory 
disease, several methods to specifically affect eosinophilic activity have been 
studied. Treatment using antibodies directed against IL-5 would, given the 
strong effect of IL-5 on both the development and activation of eosinophils, 
be expected to have a large impact on the disease.1, 36 However, the few 
placebo-controlled studies performed to date showed only limited effects on 
either the symptoms and the grade of eosinophilia.24, 25, 53, 54 Another cytokine 
that is mainly produced by Th2 cells, interleukin-13 (IL-13), affects 
eosinophils in a manner similar to IL-5 and recently, a placebo-controlled 
study in 25 EoE patients incorporating treatment with a specific inhibitor of 
IL-13 activity was carried out. A decrease in the eosinophilic load and a trend 
toward improved clinical symptoms was noted at the 6-month follow-up.55 
Another method for inhibiting the activity of the eosinophils was studied in a 
placebo-controlled trial in which EoE patients were given a course of 
treatment with an antagonist of the chemoattractant receptor-homologous 
molecule on Th2 cells. An anti-eosinophilic effect was found, with reduction 
of the eosinophilic load, but only modest beneficial clinical effects were 
seen.56  
 
1.5.5 Proton-Pump Inhibitor-Responsive 
Esophageal Eosinophilia  
Recently, a new ailment called proton-pump inhibitor-responsive esophageal 
eosinophilia (PPI-REE) has been described. PPI-REE patients, like EoE 
patients, exhibit eosinophil peak values that exceed 15/HPF but respond well 
histologically and/or symptomatically to PPI-treatment.25, 57 It has been 
suggested that the epithelial damage caused by acidic gastric reflux may 
facilitate antigen exposure and thereby the activation of the Th2-immune 
defense and the development of EoE in individuals with an atopic 
predisposition. It may also be the other way around; the inflammation caused 
by EoE might make the epithelium more sensitive to reflux. However, 
whether PPI-REE is truly a separate disease entity or merely the condition of 
a subset of patients with EoE who respond well to PPI treatment is not yet 
known.57, 58 Recently, studies have shown that, in addition to their anti-acidic 
effect, PPIs have anti-inflammatory and cell-stabilizing effects on the 
esophageal mucosa. In vitro experiments have also shown that PPIs affect the 
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Th2 cytokine and eotaxin-3 (an eosinophil chemoattractant) expression levels 
and thus, they may affect the potential mechanism limiting the immune-
driven responses in the target organ.16, 59, 60 To rule out PPI-REE in patients 
suspected of having EoE, a 2- month course of PPI treatment followed by 
endoscopic re-examination including biopsies are recommended.24, 25 To date, 
no other diagnostic tests have been found to distinguish PPI-REE from EoE, 
and the controversy regarding the optimal management of these patients 
persists. 
 
Table 1. Overview of randomized controlled trials of treatment for adult EoE patients.    
*= Ages 3-30 years. **Ages >14 years. 
Title Author      
/Year 
Treatment Design Results 
Eosinophilic 
esophagitis in adults is 
associated with IgG4 
and not mediated by 
IgE 
Clayton et 
al. 2014 54 
Omalizumab 
(n=16)          
/placebo (n=14)  
Rand. 
double-
blind.   
No reduction in the 
eosinophil count or 
symptoms in the 
treatment group 
compared with the 
placebo group. 
Efficacy, dose 
reduction, and 
resistance to high-dose 
fluticasone in patients 
with eosinophilic 
esophagitis 
Butz et al. 
2014 43 
Fluticasone 
propionate 
1760 mcg/d 
(n=28) /placebo 
(n=14) 
Rand. 
double-
blind. *  
Reduced eosinophil 
count in 65% of the 
treated group and 0% of 
the placebo group.  
 
Randomized controlled 
trial comparing 
aerosolized swallowed 
fluticasone to 
esomeprazole for 
esophageal 
eosinophilia  
Moawad et 
al. 2013 61 
Fluticasone  
880 mcg/d 
(n=21)            
/Esomeprazole 
40 mg/d (n=21) 
Rand.  
single-
blind.  
No change in the 
eosinophil count in any 
of the treatment groups.  
Symptoms improved in 
the esomeprazol but not 
in the fluticasone group.  
Similar improvement of 
the endoscopic findings 
in both groups.  
Anti-eosinophil activity 
and clinical efficacy of 
the CRTH2 antagonist 
OC000459 in 
eosinophilic 
esophagitis 
Straumann 
et al. 2013 
56 
OC000459   
200 mg/d 
(n=14)       
/placebo (n=12)  
Rand. 
double-
blind. 
 
Decreased eosinophil 
count and reduction in 
physician-reported 
disease activity in the 
treatment group.  
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Viscous topical is more 
effective than nebulized 
steroid therapy for 
patients with 
eosinophilic 
esophagitis 
Dellon et 
al. 2012 62 
Budesonide 
2mg/d 
nebulized 
(n=11)            
/viscous slurry 
(n=11) 
Rand.  
 
Decreased eosinophil 
count in the viscous-
slurry group. Dysphagia 
was relieved in both 
groups 
Swallowed fluticasone 
improves histologic but 
not symptomatic 
response of adults with 
eosinophilic 
esophagitis 
Alexander 
et al. 2012 
44 
Fluticasone 
1760 µg/d     
(n=21)                
/placebo (n=15)  
Rand. 
double-
blind.   
Decreased eosinophil 
count in the treatment 
group. No change in 
dysphagia between the 
groups.  
Budesonide Is Effective 
in Adolescent and 
Adult Patients With 
Active Eosinophilic 
Esophagitis  
Straumann 
et al. 2010 
42 
Budesonide     
2 mg/d (n=18)    
/placebo (n=18) 
Rand. 
double-
blind. 
** 
Decreased eosinophil 
count and reduced 
dysphagia in the 
treatment group.  
Long-Term Budesonide 
Maintenance 
Treatment Is Partially 
Effective for Patients 
With Eosinophilic 
Esophagitis  
Straumann 
et al. 2011 
45 
Budesonide  
0,5 mg/d 
(n=14)  
/placebo (n=14) 
Rand. 
double-
blind. 
** 
Eosinophil count 
increased more in the 
placebo group than in 
the treatment group. 
Dysphagia increased in 
the placebo group. 
Comparison of 
esomeprazole to 
aerosolized, swallowed 
fluticasone for 
eosinophilic 
esophagitis 
Peterson et 
al. 2010 63 
Esomeprazole 
40 mg/d (n=15) 
/Fluticasone 
880 mcg/day 
(n=15)  
Rand. Decreased eosinophil 
count in the 
esomeprazole group 
and decreased count in 
the fluticasone group 
(although not 
statistically significant). 
No difference in 
dysphagia between the 
groups. 
Anti-interleukin-5 
antibody treatment 
(mepolizumab) in 
active eosinophilic 
oesophagitis: a 
randomised, placebo-
controlled, double-
blind trial 
Straumann 
et al. 2010 
53 
Mepolizumab 
750 mg/week 
(n=5)       
/placebo (n=6)  
Rand. 
double-
blind  
Decreased eosinophil 
count in the treatment 
group. 
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1.6 Health-Related Quality of Life 
Quality of Life (QoL) is a term with many interpretations. The World Health 
Organization has defined the concept of QoL as “individuals’ perceptions of 
their position in life in the context of the culture and value systems in which 
they live and in relation to their goals, expectations, standards and 
concerns.”64 Health-Related Quality of Life (HRQL) is an important aspect of 
clinical research. HRQL concerns factors that affect the individual, not only 
the occurrence or absence of disease but also the impact of the disease on 
mental and social health.65 Several methods for measuring HRQL have been 
developed, including various interviewing techniques and the use of specific 
questionnaires. Patient-Reported Outcomes (PRO) is a collective expression 
of information regarding a patient’s health that is provided by the patient her- 
or himself without the interference of anyone else. PRO can be used to 
evaluate symptoms and HRQL through structured interviews or 
questionnaires. The use of questionnaires reduces the risk that the observer 
might under- or over-estimate the actual HRQL status. This method also 
reduces the possibility of biased answers, which might occur during 
interviews, for instance. There are numerous instruments available today for 
measuring HRQL. These are commonly divided into generic or disease-
specific categories.65 
Generic HRQL-evaluation instruments have been developed for general use 
and provide an overall picture, independent of the patient’s condition or 
symptoms. Examples of a widely used generic HRQL questionnaire are the 
EuroQol-5D and the Short-Form-36 (SF-36).66, 67 In contrast, disease- and/or 
symptom-specific instruments have been developed to focus on issues 
relevant to a specific disease or condition. There are several such 
questionnaires available today, such as the European Organisation for 
Research and Treatment of Cancer Quality of Life Questionnaire Core 30 
(EORTC QLQ-C30), which was designed to evaluate important detailed 
aspects specifically for cancer patients, and the EORTC QLQ Oesophageal 
18 module (EORTC QLQ-OES18), which focus on issues specifically 
relevant for patients with esophageal cancer, including their grade of 
dysphagia.68-70 In the two latter questionnaires, the questions are organized 
into different domains and the answers are transformed to scales with scores 
ranging from 0 to 100.71 When interpreting the outcome of the scoring, and as 
a complement to statistically significant differences, clinically significant 
differences in the scores are also commonly evaluated, which allows 
individual changes of importance to be indentified.72, 73 
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2 AIMS 
The overall aim of this thesis was to investigate clinical issues relevant to the 
management of adult patients with EoE.  
Study I  
To evaluate a potential seasonal variation in the incidence of esophageal 
bolus impaction leading to hospital admittance. In addition, by excluding 
cases that involved sharp objects, atresia, cancer and the lack of coexisting 
allergic or other atopic disorders, verify whether such a variation could be 
traced to a subgroup with a high probability of having concurrent EoE. 
Study II  
To establish the baseline characteristics regarding dysphagia and HRQL in 
patients newly diagnosed with EoE and to survey the outcome after a 2-
month course of treatment with topical corticosteroids.  
Study III 
To survey the outcome including symptoms and HRQL at least one year after 
diagnosis in a cohort of EoE patients who were treated with a 2-month course 
of topical corticosteroids.  
Study IV 
To evaluate potential correlations between the symptoms/HRQL and the 
grade of mucosal eosinophilia in the proximal and distal part of the 
esophagus of patients with dysphagia and esophageal eosinophilia. 
Additionally, to compare the standard hematoxylin-eosin (HE) staining 
method with an immunohistochemical (IHC) technique detecting Eosinophil 
Major Basic Protein (EMBP) for assessing eosinophil peak count. 
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3 PATIENTS AND METHODS 
The patients included in the four studies described in this thesis were 
admitted to hospital due to esophageal bolus impaction (Study I) and/or were 
diagnosed with EoE according to the consensus-recommendations of 2007 
(Study II-IV) (Table 2).23 PPI-testing in order to exclude PPI-REE according 
to the recommendations of 2013 was not used as a criterion for inclusion.25 
Patients were recruited for the studies between January 2004 and the end of 
December 2012. The vast majority of patients was recruited in the Ear, Nose 
and Throat (ENT) Department at NÄL Medical Center Hospital, Trollhättan, 
Sweden (a secondary referral center that serves approximately 275 000 
inhabitants), and a few patients were recruited in the ENT-department at 
Sahlgrenska University Hospital, Gothenburg, Sweden. 
 
Table 2. Demographic data for the participants in studies I-IV.    
*Presence of allergies in cases with soft food bolus impaction (n=223) 
 
  
 I II III IV 
No. of patients 314 31 47 65 
Mean age, range (years) 57, 1-104 45, 18-89 49, 18-90 45, 19-88 
Gender (males) 200 (65%) 23 (74%) 37 (79%) 48 (74%) 
Concurrent allergic 
diatheses 90 (40%)* 21 (68%) 32 (68%) 47 (72%) 
Events of esophageal     
bolus impaction 314 (100%) 14 (45%) 23 (49%) 26 (40%) 
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Study I included all of the patients with esophageal bolus impaction who 
were admitted to NÄL Medical Center Hospital during a 6-year period 
(January 1st 2004 to December 31st 2009). The case records were reviewed 
for demographic data, type of foreign body, medical history, including the 
presence of allergies or other atopic disorders and the time of the year of the 
incident (month and season).  
The seasonal incidence of the event was calculated for all of the patients, and 
was recalculated after exclusion of the cases involving swallowed sharp 
items, cancer and atresia. Cases with and without an atopic diathesis were 
also analyzed separately (Figure 7).  
 
 
Figure 7. Flow-chart of the exclusion procedure of Study I.  
  
All cases  
(n=314) 
Allergy/atopy 
(n=90) 
Non allergy/atopy 
 (n=133) 
Sharp items  
(n=77) 
Cancer/atresia  
(n=14) 
Soft food  
(n=223) 
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Studies II, III and IV included a total of 83 individual, untreated patients 
who were diagnosed with EoE. Dysphagia-related symptoms and the HRQL 
were evaluated using the WDS scale and the EORTC QLQ OES-18 and SF-
36 questionnaires. In addition, a thorough review of the medical records was 
conducted and each patient’s data regarding the presence of allergies, type of 
allergy testing performed, history of esophageal bolus impaction events and 
endoscopic findings were recorded.  
In Studies II and III, the EoE patients included were asked to complete the 
three questionnaires before and after treatment with a 2-month course of 
aerosolized mometasone furoate, 50 µg per spray, 4 sprays per dose taken 4 
times daily. Patients were instructed to administer the doses orally after each 
meal (breakfast, lunch, and dinner) and before bedtime, and the patients were 
not allowed to eat or drink for 30 minutes after drug intake. The 
administration and duration of the treatment followed the recommendations 
of the American Gastroenterology Association (AGA) Institute, with the 
exception that mometasone furoate was used instead of fluticasone or 
budesonide, although at an equivalent dosage.23 At the follow-up directly 
after the 2-month treatment course, the patients completed the questionnaires 
and were interviewed regarding their compliance and the effects of the 
treatment, including possible side-effects and adverse events. In Study III, a 
third evaluation was performed at least one year after the diagnosis. At this 
long-term follow-up, the formerly mentioned questionnaires were 
administered again, and in addition, a non-validated questionnaire comprising 
questions focusing on medication and hospital visits was administered. The 
patients were able to answer the latter questions in free text, but the answers 
were categorized for analytical purposes. 
In Study IV, untreated patients with dysphagia and esophageal eosinophilia 
were asked to complete the questionnaires in connection with diagnostic 
endoscopy that included 3-4 biopsies from both the distal and the proximal 
part of the esophagus. The biopsies were processed routinely by fixation 
using 4% formaldehyde, embedded in paraffin wax and cut into 3-5 µm tissue 
sections that were HE stained. New tissue sections were later cut from the 
original frozen paraffin blocks. Prior to IHC staining, which involved 
antigen-antibody interactions and visualization using a marker, the tissue 
sections were pretreated with Proteinase K for epitope retrieval, thereby 
facilitating the interaction of the antibody with the antigen. A peroxidase-
blocking step was performed to prevent nonspecific binding. The 
EnVisionTM Detection System, a two-step visualization system, was used to 
perform IHC staining. First, the sections were treated with the primary 
antibody, a mouse monoclonal antibody directed against human eosinophil 
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major basic protein (EMBP) (Santa Cruz Biotechnology Inc. Tex. USA; 
clone BMK13, ref. K5007). Next, to allow visualization of the antibody, a 
polymeric system with a dextran backbone that was conjugated to various 
enzymes and to antibody molecules directed against rabbit and mouse 
immunoglobulin was applied. Using a substrate solution of concentrated 
diaminobenzidine and chromogen and a hydrogen peroxide-containing 
buffer, the sites containing the target antigen were stained brown, and the 
nuclei were stained blue by HE counterstain. The IHC staining was 
conducted using a positive control. The stained slides were scanned and were 
anonymously viewed using the computer program Aperio ImageScope 
(Aperio Technologies, Vista, CA, USA), and the eosinophils in a high-power 
field were counted to determine the peak values.  
  
Aspects on the Management of Patients with Eosinophilic Esophagitis 
26 
3.1 Questionnaires 
Currently, there are several scales and questionnaires with the potential to 
determine the grade of dysphagia and/or the HRQL of EoE patients (Table 3). 
The following scales and questionnaires were used in the research described 
in this thesis: 
The Watson Dysphagia Scale (WDS) is an instrument for evaluating the 
grade of esophageal dysphagia. The WDS scale provides a score ranging 
from 0 (no dysphagia) to 45 (severe dysphagia) based on a 9-item assessment 
(ranging from liquids to solid food). The occurrence of dysphagia for each 
liquid or solid substance is determined by the patient and scored on a 3-point 
Likert scale (1=always, 0.5=sometimes, and 0=never); see Appendix 1. This 
score is then multiplied by a factor for each substance, and the scores for all 
of the substances are summed.74, 75  
Although the WDS scale has not been properly validated according to the 
current recommendations, objective evaluations of it have been performed.75 
In a clinical study, patients with dysphagia were asked to eat various food 
items within 20 minutes. The outcome was scored according to the results of 
the WDS evaluations, which showed a high correlation of dysphagia and the 
ability to ingest the food items. The WDS scale has also been used in several 
studies involving patients with various etiology of esophageal dysphagia.74-78 
The European Organization for Research and Treatment of Cancer Quality 
of Life Questionnaire Oesophageal Module 18 (EORTC QLQ-OES18) was 
originally designed to investigate problems due to the location of esophageal 
cancer and its treatment.69, 70 However, because the majority of the questions 
are not cancer specific, this questionnaire has been used in various HRQL 
studies, and its cross-cultural validity and psychometric properties are 
considered satisfactory. The questionnaire comprises the following: the 
dysphagia-, eating-, reflux-, and local-pain scales and six single questions 
concerning the related symptoms, and the scores are calculated according to 
the EORTC scoring manual.71 The questions are scored by the patient on a 4-
point Likert scale (not at all, sometimes, most of the time, and always), and 
the 4 points are transformed into a score ranging from 0 to 100, in which a 
high score represents a high level of symptoms/problems; see Appendix 2. A 
one-week time frame is used. 
The Short Form-36 (SF-36) questionnaire is a multipurpose general-health 
survey consisting of 36 questions, which yields an 8-scale profile of 
functional health and well-being scores as well as psychometrically based 
physical and mental health summary values. This questionnaire has been used 
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in numerous studies, and its validity is well documented.79-81 The patient 
answers the questions using a 2-, 3-, 5-, or 6-grade Likert scale, respectively, 
and a 4-week time frame is used. The scores are transformed into a score 
ranging from 0 to 100, in which a high score represents a high level of 
functioning/well-being; see Appendix 3. 
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Table 3. A selection of questionnaires potentially relevant for evaluating 
dysphagia in adult EoE patients. 
Instrument Author      
/ Year 
Contents Original 
population 
Adult Eosinophilic 
Esophagitis Activity 
Index (EEsAI)  
Schoepfer 
et al. 2014 
82 
45 items, 5 domains: 
general-, 2symptom-, 
comorbidities and 
medication. 
Adults with EoE 
Adult eosinophilic 
oesophagitis quality of 
life questionnaire    
(EoO-QOL-A)  
Taft et al. 
2011 83 
37 items, 5 subscales: 
eating/dietary-, 
social-, emotional-
impact, disease and 
choking anxiety.  
Adults with EoE 
Esophageal Symptoms 
Questionnaire (ESQ)  
Kwiatek et 
al. 2011 84 
30 items, 3 subscales: 
dysphagia, globus 
sensation, and reflux 
symptoms. 
Patients with 
esophageal and 
throat complaints 
including but not 
requiring globus 
sensation 
Mayo Dysphagia 
Questionnaire-30  
(MDQ-30)  
McElhiney 
et al. 2009 
85 
28 items, 3 domains: 
dysphagia, heartburn 
and regurgitation. 
Adult with 
esophageal diseases 
Eating assessment tool     
(EAT-10)  
Belafsky et 
al. 2008 86 
10 items measuring 
different aspects of 
dysphagia. 
Patients with a wide 
variety of causes of 
dysphagia 
European Organization 
for Research and 
Treatment of Cancer 
Quality of Life 
Questionnaire- 
Oesophageal Module 18                    
(EORTC QLQ-OES 18)  
Blazeby et 
al. 2003 70 
18 items, 4 subscales: 
dysphagia, eating, 
reflux, and local-pain 
scales and 6 single 
questions. 
Patients with 
esophageal cancer 
Watson Dysphagia Scale 
(WDS)  
Dakkak et 
al. 1992 75 
Occurence of 
dysphagia for 9 
substances (ranging 
from liquids to solid 
food). 
Patients with 
benign esophageal 
strictures 
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3.2 Statistics and Ethics 
Non-parametric statistical tests were used in the studies described in this 
thesis (with the exception of Study I) for non-normally distributed variables, 
such as symptom scores and cell counts. All of the significance tests were 
two-tailed and were conducted using the 5% significance level. The mean, 
median, standard deviation, and range values were used for descriptive 
purposes.  
Study I The binomial test was used to analyze dichotomous data. The χ2 test 
with 3 degrees of freedom was used to analyze discrete data that were 
distributed into four categories.  
Study II & III The mean, median, standard deviation, and range were used 
for descriptive purposes, and the Wilcoxon matched-pairs signed-rank test 
was used to compare the questionnaire scores obtained at each time point.  
Study IV Spearman’s correlation coefficients were used to analyze 
correlations. For comparison between groups, the Mann-Whitney U-test was 
used in the case of continuous variables. The statistical analyses were 
performed using Statistiska Konsultgruppen, Göteborg (www.stat-grp.se). 
The studies were performed in accordance with the Declaration of Helsinki 
and were approved by the Regional Ethical Committee of the University of 
Gothenburg (D Nr 388-12). Informed consent was obtained from each 
participant before inclusion (studies II-IV).  
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4 STUDY DESIGNS 
Study I: 
Case series with chart review. A retrospective cohort analysis was performed, 
including patients with esophageal bolus impaction who were admitted to 
NÄL, Medical Center Hospital, Trollhättan, Sweden during a 6-year period 
(2004-2009). Step-by-step analysis regarding the seasonal variation of 
incidence was performed for the entire cohort, for cases with soft bolus 
impaction and then after subdividing the patients according to the presence or 
absence of coexisting atopic disorders. 
Study II: 
Case series with planned data collection. A prospective study of 
consecutively included EoE patients, with assessment of dysphagia-related 
symptoms and the HRQL before and after a 2-month course of treatment 
using topically administered mometasone furoate. 
Study III:  
Cross-sectional cohort study. EoE patients treated with a 2-month course of 
topically administered mometasone furoate were evaluated regarding 
dysphagia-related symptoms and the HRQL, medication and complications at 
least one year after diagnosis. 
Study IV: 
A retrospective correlation analysis. Dysphagia-related symptoms and HRQL 
of untreated patients with dysphagia and esophageal eosinophilia were 
evaluated in conjunction with esophageal biopsy findings, and the results 
were correlated with the grade of mucosal eosinophilia. 
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5 RESULTS 
Study I  
During the 6-year inclusion period, 314 cases (302 individual patients) were 
admitted to NÄL Medical Center Hospital due to esophageal bolus 
impaction. A significantly higher incidence of this event was found during 
the summer and fall than during the winter or spring (p=0.048). After 
excluding cases involving accidental or structural causes as well as those 
without coexisting atopic disorders, leaving a group with soft food bolus 
impaction and a coexisting atopic disorder (n=90), an even stronger seasonal 
variability appeared (p=0.004), including an unprejudiced general variation 
among the four seasons (p=0.015). A corresponding variation was found 
among the 24 cases (22 individuals) in which EoE was diagnosed (p=0.04). 
In contrast to these findings, no seasonal variation was found in the group of 
patients with soft-food bolus impaction but without a coexisting atopic 
disorder (n=133) (Figure 8).   
 
 
Figure 8. The seasonal variation in cases with soft food bolus impaction with (n=90) 
or without (n=133) a coexisting atopic disorder and in cases with coexisting EoE 
(n=24). 
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Study II 
Thirty-one consecutive, newly diagnosed, untreated EoE patients were 
recruited to the study during a one-year period. None of the patients declined 
participation. The aforementioned questionnaires were completed both at 
inclusion and after treatment. Significant improvements were found for 
several of the dysphagia-related scales and items, including the overall WDS 
score (Figure 9), the EORTC QLQ-OES18 dysphagia and eating scores, and 
the score for the problems-with-choking item. In addition, improvements 
were found in the SF-36 item scores for bodily pain, general health, social 
functioning and mental health, whereas the EORTC QLQ-OES18 item score 
for trouble-with-coughing worsened. The information collected through the 
interviews indicated that the treatment was well accepted and that the level of 
compliance was high. One patient experienced side effects and developed 
oral candidiasis two weeks after the initiation of the treatment. The condition 
was successfully treated with topical antifungal medication (amphotericin B), 
and the patient continued the corticosteroid treatment throughout the study 
period. No other adverse events were reported during the trial or during the 
follow-up visits. 
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Figure 9. Results of the assessment of the dysphagia of patients prior to treatment 
and after a 2-month course of mometasone furoate treatment, performed using the 
Watson dysphagia scale. 
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Study III 
Of 51 eligible EoE patients, 48 completed the questionnaires. One patient 
declined participation, two did not answer despite several reminders, and one 
patient was excluded due to the existence of a concomitant esophageal 
disease (scleroderma). Consequently, 47 patients (92%) were included 
(January, 2009 to March, 2011) in the study, and the median time from 
diagnosis to the long-term follow-up was 23 months (range, 13-34). 
Consistent with the results of Study II, the WDS scores as well as the 
EORTC QLQ-OES18 dysphagia, eating and choking scores were all 
significantly improved after the 2-month course of treatment compared with 
those observed at the time of diagnosis. In the case of the WDS and EORTC 
QLQ-OES18 dysphagia-and eating scores, the improvements persisted at the 
time of the long-time follow-up, a finding that was not observed for the 
choking-item score. However, the WDS-based scores declined significantly 
from directly after treatment began to the time of the long-term follow-up 
(Figure 10). According to the results obtained using the supplementary 
questionnaire that was provided at the long-term follow-up, the majority of 
the patients reported having experienced episodes of aggravated swallowing 
difficulties and esophageal bolus impaction during the study period. Even so, 
according to the medical records, none of these patients was referred to a 
hospital for the retrieval of an impacted bolus, none of the patients underwent 
endoscopic dilatation, and most of the patients received only the initial 2-
month course of topical corticosteroid treatment after the diagnosis. 
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Figure 10. Results of the assessment of the dysphagia of patients prior to treatment, 
after a 2-month course of mometasone furoate treatment and at the long-term follow-
up at least one year after diagnosis performed using the Watson Dysphagia Scale. 
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Study IV 
Of 83 eligible, untreated patients with dysphagia and esophageal eosinophilia 
(September 2007 to December 2012), four patients declined to participate in 
the study, and 12 were excluded from analysis due to missing questionnaires. 
Furthermore, two of the histopathology slides could not be examined due to 
unsuccessful staining, why 65 patients were considered in the final analysis. 
Regardless of the staining method (HE or IHC) used (Figure 11 and 12), no 
significant correlation was found between the grade of eosinophilia and the 
symptom or HRQL scores.  
The average number of eosinophils detected using the IHC technique was 
twice as high as that detected using the HE staining technique (mean value: 
70.9 vs. 34.5). Patients diagnosed in conjunction with an event of acute bolus 
impaction had an increased grade of eosinophilia in biopsy samples taken 
from the proximal part of the esophagus compared to that of subjects without 
concomitant bolus impaction.  
 
Figure 11.  HE stained esophageal mucosal biopsy sample taken from     
an EoE patient. 
 
Figure 12. IHC stained esophageal mucosal biopsy sample taken from      
an EoE patient. 
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6 DISCUSSION AND FUTURE 
PERSPECTIVES 
The research described in this thesis confirmed that there is a seasonal 
variation in the incidence of acute esophageal bolus impaction in patients in 
which a causative effect of diagnosed or undiagnosed EoE might be 
suspected, that untreated EoE patients may have a high burden of symptoms 
that respond well to a 2-month course of topical corticosteroid treatment and 
that this response may persist for a more than a year. Furthermore, it was 
found that the vast majority of EoE patients have had symptoms for many 
years before diagnosis and that a high proportion of them experienced at least 
one episode of an acute bolus impaction that required retrieval before the 
diagnose was established. 
Study I was designed with the knowledge that a seasonal variation in the 
incidence of EoE was previously demonstrated and that patients with an 
impacted esophageal bolus requiring endoscopic removal have been shown, 
in approximately 30 to 50% of cases, to have concomitant EoE.10, 11, 87, 88 At 
the time of patient inclusion (2004 to 2009), the awareness of the importance 
of obtaining biopsies from patients admitted to the hospital due to esophageal 
bolus impaction was still low in the ENT department of NÄL Hospital 
Medical Center. The clinical signs and conceivable complications of EoE had 
not reached out to every single doctor on call. Therefore, only a limited 
fraction of the patients in this study were properly biopsied during the acute 
endoscopic removal of the foreign body, a procedure that currently has 
become routine or at least much more common in our department. We found 
a seasonal variation in the incidence of acute esophageal bolus impaction, 
with the highest incidence observed during the summer and fall. Furthermore, 
this variation was traced to a subgroup with symptoms or signs of a 
coexisting atopic disorder and therefore a higher likelihood of underlying 
EoE. Knowing this, one must be careful to not over-interpret these results 
because the existence of an atopic diathesis is not a very firm criterion and 
there may be other explanations for the observed variance. To prove such 
causation would demand a prospective study with firm criteria regarding the 
allergic status of the patients and adequate biopsy collection in all cases of 
bolus impaction. Furthermore, to evaluate a potential seasonal variation in 
symptom severity and/or the HRQL, a prospective study in which the 
appropriate instruments for this assessment were applied repeatedly 
throughout the year is needed. Nevertheless, the clinical consequence of the 
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first study is that henceforth EoE should be suspected in all cases of 
esophageal bolus impaction warranting proper biopsies and the investigation 
of allergies. 
In Studies II and III, surveys of the baseline characteristics regarding the 
dysphagia and HRQL of untreated patients with EoE were performed using 
the WDS scale and the EORTC QLQ-OES18 and SF-36 questionnaires. A 
substantial burden of symptoms was found, with a significant improvement 
observed after a 2-month course of treatment using orally administered 
mometasone furoate. Our results support the previous demonstrations of the 
favorable effects of topical corticosteroid treatment in EoE patients.42, 61, 62, 89 
The reasons for selecting mometasone furoate as the “drug of choice” for our 
patients included our previous experience with the substance and its low 
systemic availability. However, although we used the equivalent dosage and 
administration technique described in the consensus document, the optimal 
duration and need for repeated courses of topical mometasone furoate 
treatment have not been fully evaluated. A randomized, placebo-controlled 
trial with repetitive follow-ups, including assessments of complications such 
as the development of fibrosis is warranted to assess causality and evaluate 
the long-term effects. 
In the long-term follow-up evaluations performed in Study III, the 
improvement in the dysphagia-related symptoms was found to persist, at least 
to a certain degree, at more than one year after the diagnosis. Whether the 
reason for this long-lasting improvement was pharmacological or merely the 
consequence of an increased awareness of the disease among the patients, 
resulting in the modification of eating habits, should also be subjected to 
further investigation. Interestingly, according to the medical records, none of 
the patients required the retrieval of an impacted bolus during the follow-up 
period, indicating that the incidents reported in the supplementary 
questionnaire were most likely transient and self-resolving. Consistent with 
this hypothesis, Kuchen et al. found in a study of 206 EoE patients (with a 
median follow-up period of five years) that oral topical corticosteroids 
resulted in a reduced risk (OR 0.41) of the occurrence of future esophageal 
bolus impaction.47 In addition, the results of Study III showed that more than 
half of the patients required only one 2-month course of corticosteroid 
treatment after diagnosis, and that among the patients who reported repeated 
treatment, the majority had undergone only one, or less commonly, two extra 
courses of treatment. These findings, together with the improved scores 
obtained using the WDS scale and the EORTC QLQ OES-18 questionnaire, 
further supported the prolonged effect on dysphagia obtained after the 
initiation of treatment. The outcome of the WDS evaluation at the long-term 
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follow-up, not only showed a significant improvement compared with the 
conditions at the time of inclusion, but also demonstrated a deteriorated 
outcome compared with that after the 2-month course corticosteroid 
treatment. This finding indicated, quite reasonably, a slow but declining 
effect of the initial treatment over time and highlighted the superior ability of 
the WDS scale for detecting minor changes in dysphagia compared with that 
of the other scales used in this study. In other words, the WDS scoring of 
dysphagia for the nine ranked food items performed by the patients resulted 
in a higher sensitivity compared with that observed when the patients 
answered the three questions on the EORTC QLQ-OES18 Dysphagia 
questionnaire. Altogether, the WDS scale and the EORTC QLQ- OES18 
questionnaire appear to be clinically useful instruments for surveillance over 
time and the detection of changes in dysphagia-related symptoms and the 
HRQL of EoE patients. However, using questionnaires that were specifically 
designed and therefore properly validated for EoE patients would 
unquestionably yield more reliable results in future studies. Taft et al. 
recently developed a quality of life questionnaire for evaluating adult EoE 
patients.83 The validation analysis demonstrated reliable results for patients 
without a confirmed diagnosis, and according to the author, this questionnaire 
should be re-validated with patients who have been diagnosed according to 
the EoE-consensus recommendations. Just recently, Schoepfer et al 
developed and validated a symptom-based activity index instrument 
specifically for use in adults with EoE. 82  
EoE is defined as a clinicopathological disease and therefore both its 
symptoms and eosinophilia in the esophageal mucosa are required to meet the 
diagnostic criteria. In Study IV, we evaluated any potential correlation 
between the symptoms/HRQL and the histological findings of untreated 
patients with dysphagia and esophageal eosinophilia. An association would, 
at least theoretically, add credibility to the diagnostic criteria, particularly 
because eosinophils are likely to contribute to esophageal dysfunction.81 
Contrary to our initial hypothesis, no such correlation could be found 
regardless of level of the biopsies or the questionnaire used. Our findings 
were also somewhat contradictory to the results of Pentiuk et al., who found 
a modest correlation between the symptoms and the peak distal eosinophil 
count (r2=0.37) of a group of 15 untreated children and adolescents with 
EoE.90 However, in that study, in which 49 subjects were evaluated using the 
pediatric EoE symptom score (PEESS), histological remission after treatment 
was associated with symptomatic improvement. In a placebo-controlled trial, 
Alexander et al. also demonstrated a similar inconsistent correlation between 
the effect of treatment on the symptoms and the eosinophil counts.44  
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The observed lack of correlation between the number of eosinophils observed 
and the severity of symptoms may be due to several factors, and a 
discrepancy was previously observed.91
 
Although the diagnostic criteria of 
>15 eosinophils/HPF and the presence of symptoms of esophageal 
dysfunction has high sensitivity and specificity, EoE is known to be a patchy 
disease.24, 92, 93 Straumann et al. reported that biopsy samples taken from 
regions of the mucosa with white exudates had a higher density of 
eosinophils compared with that in biopsy samples taken from the regions of 
mucosa with a normal endoscopic appearance. They also noted that a higher 
symptom score, as assessed through an interview, was associated with a 
higher occurrence of whitish exudates.92 A future prospective study designed 
to evaluate this correlation through the use of disease-specific questionnaires 
and biopsy forceps that allow the collection of biopsy material not only from 
the superficial part of the mucosa but also from the underlying lamina 
propria, allowing an assessment of fibrosis development, would be desirable. 
The results of such a study would be likely to facilitate the evaluation of 
various treatment strategies and to increase the possibility of individualizing 
the management of EoE patients. 
Although no correlation was found between symptom severity and the grade 
of eosinophilia in our study, subjects with concomitant bolus impaction were 
found to have a significantly higher number of eosinophils in the proximal 
part of the esophagus (p<0.05 based on HE staining and p<0.05 based on 
IHC staining), a finding that, to the best of our knowledge, has not been 
previously described. Whereas a possible explanation for this result might be 
the temporary irritation caused by the food bolus, followed by the recruitment 
of eosinophils from the blood supply, an increased peak value of eosinophils 
in the proximal part of the esophagus was previously suggested to have a 
greater diagnostic impact than the corresponding value in the distal part of 
this organ.94, 95 Our findings thus could support greater attention being given 
to the proximal part of the esophagus of EoE patients.  
The second aim of Study IV was to compare the eosinophil counts obtained 
using the standard HE staining method with those obtained using an IHC 
technique for detecting EMBP in the mucosa. Significantly higher eosinophil 
counts were obtained using IHC staining than were obtained using HE 
staining, a finding that is basically uncontroversial.96, 97 Mueller et al. found a 
significantly higher number of intraepithelial eosinophils using (using 
antibodies directed against Major Basic Protein) IHC staining than with HE 
staining, in a study of 30 EoE patients.96 This result was confirmed by the 
same authors in a study comparing the histological parameters of EoE and 
GERD.97 Dellon et al. found that IHC staining distinguished EoE patients 
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from controls (patients examined endoscopically due to dysphagia or GERD 
symptoms), although using this method did not distinguish EoE patients from 
patients with PPI-REE.98 Nevertheless, today HE staining is a well-
established method, and more evidence is definitely needed before changing 
current practice. Prospective studies with firm diagnostic criteria comparing 
various mucosal staining techniques combined with inter-observer analyses 
could be fruitful steps in this direction. 
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7 CONCLUSIONS 
 
The following conclusions could be drawn from the results of the studies 
described in this thesis: 
• A seasonal variation in the incidence of esophageal bolus 
impaction was confirmed. 
 
• The seasonal variation was pronounced in patients with a 
coexisting atopic diathesis. 
 
• A causative effect of diagnosed or undiagnosed EoE on this 
seasonal variation might be suspected. 
 
• Dysphagia-related symptoms and the HRQL improved 
significantly in EoE patients after a 2-month course of 
topical mometasone furoate treatment.       
• A randomized placebo-controlled trial is warranted to assess 
the causality.  
• A partial remission persisted more than one year after 
diagnosis and the discontinuation of medication. 
 
• The WDS scale and the EORTC QLQ-OES18 questionnaire 
appeared to be sensitive instruments appropriate for the 
surveillance of EoE patients. However, proper validation 
studies are warranted. 
 
• A lack of correlation between the symptoms/HRQL and the 
grade of mucosal eosinophilia was found in patients with 
dysphagia and esophageal eosinophilia. 
 
• Acute bolus impaction was associated with an elevated 
grade of mucosal eosinophilia in the proximal part of the 
esophagus.  
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Appendix 1 
Watson Dysphagia Scale 
Watson Dysphagia Score 
 
1 
 
Water 
2 Milk (or thin soup) 
3 Custard (or yoghurt or pureed fruit) 
4 Jelly 
5 Scrambled egg (or baked beans or mashed potato) 
6 Baked fish (or steamed potato or cooked carrot) 
7 Bread (or pastries) 
8 Apple (or raw carrot) 
9 Steak (or pork or lamb chop) 
 
The presence of any dysphagia for each liquid or solid substance is first 
deter- mined and scored; dysphagia always = 1 point, sometimes = 1/2 point, 
never = 0 points. A score from 0 (no dysphagia) to 45 (severe dysphagia) is 
then determined by multiplying the score for each substance by the adjacent 
line number, and then summing all nine lines. 
 
Originally published:  
Watson DI, Pike GK, Baigrie RJ, et al.  
Prospective double-blind randomized trial of laparoscopic Nissen  
fundoplication with division and without division of short gastric vessels.  
Ann Surg 1997; 226(5): 642-52. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2 
EORTC QLQ-OES18 
  
 
 
EORTC  QLQ – OES18 
 
 
Patients sometimes report that they have the following symptoms or problems. Please indicate the 
extent to which you have experienced these symptoms or problems  during the past week. Please 
answer by circling the number that best applies to you.   
 
During the past week: Not A Quite Very 
  at all little a bit much 
31. Could you eat solid food? 1 2 3 4 
32. Could you eat liquidised or soft food?  1 2 3 4 
33. Could you drink liquids?  1 2 3 4 
34. Have you had trouble with swallowing your saliva?  1 2 3 4 
35. Have you choked when swallowing?  1 2 3 4 
36. Have you had trouble enjoying your meals?  1 2 3 4 
37. Have you felt full up too quickly?  1 2 3 4 
38. Have you had trouble with eating?  1 2 3 4 
39. Have you had trouble with eating in front of other people?  1 2 3 4 
40. Have you had a dry mouth?  1 2 3 4 
41. Did food and drink taste different from usual?  1 2 3 4 
42  Have you had trouble with coughing?  1 2 3 4 
43. Have you had trouble with talking?  1 2 3 4 
44. Have you had acid indigestion or heartburn?  1 2 3 4 
45. Have you had trouble with acid or bile coming into your mouth?  1 2 3 4 
46. Have you had pain when you eat?  1 2 3 4 
47. Have you had pain in your chest?  1 2 3 4 
48. Have you had pain in your stomach?  1 2 3 4 
 
 
 
 
 QLQ-OES18 Copyright 1999 EORTC Quality of life Group. All rights reserved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3 
SF-36 
SF36 Health Survey
INSTRUCTIONS: This set of questions asks for your views about your health.  This information
will help keep track of how you feel and how well you are able to do your usual activities.  Answer
every question by marking the answer as indicated.  If you are unsure about how to answer a
question please give the best answer you can.
1. In general, would you say your health is: (Please tick one box.)Excellent
Very Good
Good
Fair
Poor
2. Compared to one year ago, how would you rate your health in general now? (Please tick one box.)Much better than one year ago
Somewhat better now than one year ago
About the same as one year ago
Somewhat worse now than one year ago
Much worse now than one year ago
3. The following questions are about activities you might do during a typical day.  Does your healthnow limit you in these activities?  If so, how much?      (Please circle one number on each line.)
           Activities
Yes,
Limited
A Lot
Yes,
Limited A
Little
Not
Limited
At All
3(a) Vigorous activities, such as running, lifting heavy objects,
participating in strenuous sports
1 2 3
3(b) Moderate activities, such as moving a table, pushing a
vacuum cleaner, bowling, or playing golf
1 2 3
3(c) Lifting or carrying groceries 1 2 3
3(d) Climbing several flights of stairs 1 2 3
3(e) Climbing one flight of stairs 1 2 3
3(f) Bending, kneeling, or stooping 1 2 3
3(g) Waling more than a mile 1 2 3
3(h) Walking several blocks 1 2 3
3(i) Walking one block 1 2 3
3(j) Bathing or dressing yourself 1 2 3
4. During the past 4 weeks, have you had any of the following problems with your work or other
regular daily activities as a result of your physical health? 
(Please circle one number on each line.)                                                             Yes             No
4(a) Cut down on the amount of time you spent on work or other activities 1 2
4(b) Accomplished less than you would like 1 2
4(c) Were limited in the kind of work or other activities 1 2
4(d) Had difficulty performing the work or other activities (for example, it took
extra effort)
1 2
5. During the past 4 weeks, have you had any of the following problems with your work or other
regular daily activities as a result of any emotional problems (e.g. feeling depressed or anxious)?
                    (Please circle one number on each line.) Yes No
5(a) Cut down on the amount of time you spent on work or other activities 1 2
5(b) Accomplished less than you would like 1 2
5(c) Didn’t do work or other activities as carefully as usual 1 2
6. During the past 4 weeks, to what extent has your physical health or emotional problems interfered
with your normal social activities with family, friends, neighbours, or groups? (Please tick one box.)
Not at all
Slightly
Moderately
Quite a bit
Extremely
7. How much physical pain have you had during the past 4 weeks? (Please tick one box.)
None
Very mild
Mild
Moderate
Severe
Very Severe
8. During the past 4 weeks, how much did pain interfere with your normal work (including both work
outside the home and housework)? (Please tick one box.)
Not at all
A little bit
Moderately
Quite a bit
Extremely
9. These questions are about how you feel and how things have been with you during the past 4
weeks.  Please give the one answer that is closest to the way you have been feeling for each item.
(Please circle one number on each line.)
All of
the
Time
Most
of the
Time
A Good
Bit of
the Time
Some
of the
Time 
A Little
of the
Time
None
of the
Time
9(a) Did you feel full of life? 1 2 3 4 5 6
9(b) Have you been a very nervous person? 1 2 3 4 5 6
9(c) Have you felt so down in the dumps that
nothing could cheer you up?
1 2 3 4 5 6
9(d) Have you felt calm and peaceful? 1 2 3 4 5 6
9(e) Did you have a lot of energy? 1 2 3 4 5 6
9(f) Have you felt downhearted and blue? 1 2 3 4 5 6
9(g) Did you feel worn out? 1 2 3 4 5 6
9(h) Have you been a happy person? 1 2 3 4 5 6
9(i) Did you feel tired? 1 2 3 4 5 6
10. During the past 4 weeks, how much of the time has your physical health or emotional problems
interfered with your social activities (like visiting with friends, relatives etc.) (Please tick one box.)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
11. How TRUE or FALSE is each of the following statements for you? 
(Please circle one number on each line.) Definitely
True
Mostly
True
Don’t
Know
Mostly
False
Definitely
False
11(a) I seem to get sick a little easier than
other people
1 2 3 4 5
11(b) I am as healthy as anybody I know 1 2 3 4 5
11(c) I expect my health to get worse 1 2 3 4 5
11(d) My health is excellent 1 2 3 4 5
Thank You!
